Neonates exposure to parabens through medicines administered to inpatients
Copyright © 2020 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved..
OBJECTIVES: The objective of this study was to quantify parabens intake due to drug administration in neonates during hospitalization following their birth.
METHOD: A monocentric prospective study was performed into a neonatalogy unit to collect all drug prescriptions. An exhaustive list of parabens containing medicines commercialized in France was completed from Theriaque® database. This list was combined with drug prescription to establish an exposure profile to parabens. For each paraben containing medicines, a HPLC-UV assay was performed to determine the average daily intake of paraben received by hospitalized neonates.
RESULTS: More than 300 medicines commercialized in France contain at least one paraben. A combination of methylparaben and propylparaben was found in most cases. All hospitalized neonates (n=22) were exposed at least once to methylparaben and propylparaben through medicines while 50 % were exposed to ethylparaben. The average daily intake was higher in term newborns (572,0±249,0 versus 414,6±294,1μg/kg/j for methylparaben) but frequency was higher in prematures (65,0 versus 78,6% for methylparaben) as well as cumutives doses (1421,5±758,8 versus 8618,7±7922,3). These doses are lower than toxicological reference values but these latter do not take into account endocrine disrupting effects of these compounds.
CONCLUSIONS: These results highlight medicines as a high source of exposure to parabens in hospitalized neonates. It should encourage pharmaceutical companies and health professionnal to prioritize therapeutic cares without parabens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Annales pharmaceutiques francaises - 78(2020), 4 vom: 14. Juli, Seite 343-350 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Exposition des nouveau-nés aux parabènes via les médicaments administrés durant leur hospitalisation |
|---|
| Beteiligte Personen: |
Binson, G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.03.2021 Date Revised 29.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharma.2020.01.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308383613 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308383613 | ||
| 003 | DE-627 | ||
| 005 | 20231225131625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.pharma.2020.01.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1027.xml |
| 035 | |a (DE-627)NLM308383613 | ||
| 035 | |a (NLM)32253021 | ||
| 035 | |a (PII)S0003-4509(20)30005-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Binson, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neonates exposure to parabens through medicines administered to inpatients |
| 246 | 3 | 3 | |a Exposition des nouveau-nés aux parabènes via les médicaments administrés durant leur hospitalisation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2021 | ||
| 500 | |a Date Revised 29.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVES: The objective of this study was to quantify parabens intake due to drug administration in neonates during hospitalization following their birth | ||
| 520 | |a METHOD: A monocentric prospective study was performed into a neonatalogy unit to collect all drug prescriptions. An exhaustive list of parabens containing medicines commercialized in France was completed from Theriaque® database. This list was combined with drug prescription to establish an exposure profile to parabens. For each paraben containing medicines, a HPLC-UV assay was performed to determine the average daily intake of paraben received by hospitalized neonates | ||
| 520 | |a RESULTS: More than 300 medicines commercialized in France contain at least one paraben. A combination of methylparaben and propylparaben was found in most cases. All hospitalized neonates (n=22) were exposed at least once to methylparaben and propylparaben through medicines while 50 % were exposed to ethylparaben. The average daily intake was higher in term newborns (572,0±249,0 versus 414,6±294,1μg/kg/j for methylparaben) but frequency was higher in prematures (65,0 versus 78,6% for methylparaben) as well as cumutives doses (1421,5±758,8 versus 8618,7±7922,3). These doses are lower than toxicological reference values but these latter do not take into account endocrine disrupting effects of these compounds | ||
| 520 | |a CONCLUSIONS: These results highlight medicines as a high source of exposure to parabens in hospitalized neonates. It should encourage pharmaceutical companies and health professionnal to prioritize therapeutic cares without parabens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Endocrine disruptors | |
| 650 | 4 | |a Exposition | |
| 650 | 4 | |a Exposure | |
| 650 | 4 | |a Médicaments | |
| 650 | 4 | |a Neonates | |
| 650 | 4 | |a Nouveau-nés | |
| 650 | 4 | |a Parabens | |
| 650 | 4 | |a Parabènes | |
| 650 | 4 | |a Perturbateur endocriniens | |
| 650 | 7 | |a Endocrine Disruptors |2 NLM | |
| 650 | 7 | |a Parabens |2 NLM | |
| 650 | 7 | |a Preservatives, Pharmaceutical |2 NLM | |
| 650 | 7 | |a ethyl-p-hydroxybenzoate |2 NLM | |
| 650 | 7 | |a 14255EXE39 |2 NLM | |
| 650 | 7 | |a methylparaben |2 NLM | |
| 650 | 7 | |a A2I8C7HI9T |2 NLM | |
| 650 | 7 | |a propylparaben |2 NLM | |
| 650 | 7 | |a Z8IX2SC1OH |2 NLM | |
| 700 | 1 | |a Cariot, A |e verfasserin |4 aut | |
| 700 | 1 | |a Venisse, N |e verfasserin |4 aut | |
| 700 | 1 | |a Di Maio, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rabouan, S |e verfasserin |4 aut | |
| 700 | 1 | |a Beuzit, K |e verfasserin |4 aut | |
| 700 | 1 | |a Dupuis, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales pharmaceutiques francaises |d 1945 |g 78(2020), 4 vom: 14. Juli, Seite 343-350 |w (DE-627)NLM000046493 |x 0003-4509 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2020 |g number:4 |g day:14 |g month:07 |g pages:343-350 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharma.2020.01.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2020 |e 4 |b 14 |c 07 |h 343-350 | ||